Oncology study for bowel, breast, adrenocortical and hepatocellular cancers (S17ABB04)

This is a clinical study of a new investigational treatment called ABBV-176 in patients with a solid tumour that is now categorised as advanced.

ABBV-176 is given intravenously every 3 weeks for as long as the patient receives clinical benefit.

The purpose of this study is to see if ABBV-176 is safe, to determine a safe dose of ABBV-176, to see how much ABBV-176 is in the blood at various times (these tests are called “pharmacokinetics” or “PK”), and to determine if treatment with ABBV-176 leads to tumour shrinkage. This study is for patients with advanced solid tumour cancers that express a certain type of protein called Prolactin Receptor (PRLR). These solid tumours may include bowel, breast, adrenocortical and hepatocellular carcinomas.

This clinical study is currently recruiting participants.

If you would like more information, register below or call 1800 727 874.

No inpatient stay required

Weekly visits for the first 9 weeks, then visits every 3 weeks thereafter

* have solid tumours and
* have progressed on prior treatment, or are not amenable to treatment with curative intent, and no other therapy options known to provide clinical benefit

When enquiring about this clinical study please quote the study code above